웹Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a … 웹2024년 9월 1일 · Baird 2024 Global Healthcare Conference Date: Tuesday, September 13, 2024 ... durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Harvard and Broad Institute’s Cas9 patent estates and Broad Institute’s Cas12a patent estate for human medicines.

Editas: Gene Therapy Specialist Leading The Way In Eye Disease

웹2024년 12월 8일 · In a report released on December 6, Joel Beatty from Robert W. Baird maintained a Buy rating on Editas Medicine (EDIT - Research Report), with a p... 웹2024년 5월 4일 · EDIT Editas Medicine $14.18 / -0.1 (-0.70%) 04/18/22 Baird Editas Medicine price target lowered to $33 from $44 at Baird 02/25/22 SVB Securities Editas Medicine … dresses for homecoming 2022

Editas Medicine, Inc. : Bewertung von Baird zum Kaufen erhalten

웹Baird Adjusts Editas Medicine's Price Target to $33 From $44, Keeps Outperform Rating MT Newswires · 2024/04/18 21:19 09:12 AM EDT, 04/18/2024 (MT Newswires) -- Editas … 웹2024년 11월 18일 · Baird is positief over het aandeel met een koopadvies. Voorheen bedroeg het koersdoel 25 USD, maar is nu verlaagd naar 18 USD. 22 januari 2024 웹2024년 6월 4일 · Baird bewertet die Aktie positiv mit einem Kauf-Rating. 18 Juli 2024 english paper research topics